Akazawa T - Search Results

1

Potent CTLs can be induced against tumor cells in an environment of lower levels of systemic MFG-E8.

Mizote Y, Inoue T, Akazawa T, Kunimasa K, Tamiya M, Kumamoto Y, Tsuda A, Yoshida S, Tatsumi K, Ekawa T, Honma K, Nishino K, Tahara H. Mizote Y, et al. Among authors: akazawa t. Cancer Sci. 2024 Apr;115(4):1114-1128. doi: 10.1111/cas.16099. Epub 2024 Feb 8. Cancer Sci. 2024. PMID: 38332689 Free PMC article.

2

M2-like macrophage polarization in high lactic acid-producing head and neck cancer.

Ohashi T, Aoki M, Tomita H, Akazawa T, Sato K, Kuze B, Mizuta K, Hara A, Nagaoka H, Inoue N, Ito Y. Ohashi T, et al. Among authors: akazawa t. Cancer Sci. 2017 Jun;108(6):1128-1134. doi: 10.1111/cas.13244. Epub 2017 May 19. Cancer Sci. 2017. PMID: 28370718 Free PMC article.

3

Development of a vaccine based on bacteria-mimicking tumor cells coated with novel engineered toll-like receptor 2 ligands.

Akazawa T, Ohashi T, Wijewardana V, Sugiura K, Inoue N. Akazawa T, et al. Cancer Sci. 2018 May;109(5):1319-1329. doi: 10.1111/cas.13576. Epub 2018 Apr 22. Cancer Sci. 2018. PMID: 29575556 Free PMC article.

4

Prediction for oxaliplatin-induced liver injury using patient-derived liver organoids.

Tatsumi K, Wada H, Hasegawa S, Asukai K, Nagata S, Ekawa T, Akazawa T, Mizote Y, Okumura S, Okamura R, Ohue M, Obama K, Tahara H. Tatsumi K, et al. Among authors: akazawa t. Cancer Med. 2024 Feb;13(3):e7042. doi: 10.1002/cam4.7042. Cancer Med. 2024. PMID: 38400666 Free PMC article.

5

Adjuvant-mediated tumor regression and tumor-specific cytotoxic response are impaired in MyD88-deficient mice.

Akazawa T, Masuda H, Saeki Y, Matsumoto M, Takeda K, Tsujimura K, Kuzushima K, Takahashi T, Azuma I, Akira S, Toyoshima K, Seya T. Akazawa T, et al. Cancer Res. 2004 Jan 15;64(2):757-64. doi: 10.1158/0008-5472.can-03-1518. Cancer Res. 2004. PMID: 14744795

6

Adjuvant engineering for cancer immunotherapy: Development of a synthetic TLR2 ligand with increased cell adhesion.

Akazawa T, Inoue N, Shime H, Kodama K, Matsumoto M, Seya T. Akazawa T, et al. Cancer Sci. 2010 Jul;101(7):1596-603. doi: 10.1111/j.1349-7006.2010.01583.x. Epub 2010 Apr 5. Cancer Sci. 2010. PMID: 20507323 Free PMC article.

7

Dichloroacetate improves immune dysfunction caused by tumor-secreted lactic acid and increases antitumor immunoreactivity.

Ohashi T, Akazawa T, Aoki M, Kuze B, Mizuta K, Ito Y, Inoue N. Ohashi T, et al. Among authors: akazawa t. Int J Cancer. 2013 Sep 1;133(5):1107-18. doi: 10.1002/ijc.28114. Epub 2013 Mar 16. Int J Cancer. 2013. PMID: 23420584

8

In vivo transfection of cytokine genes into tumor cells using a synthetic vehicle promotes antitumor immune responses in a visceral tumor model.

Watanabe S, Takagi A, Yuba E, Kojima C, Dei N, Matsumoto A, Tanikawa J, Kawamura T, De Silva NH, Izawa T, Akazawa T, Kanegi R, Hatoya S, Inaba T, Sugiura K. Watanabe S, et al. Among authors: akazawa t. FASEB J. 2023 Nov;37(11):e23228. doi: 10.1096/fj.202202036R. FASEB J. 2023. PMID: 37815518

9

[Tracheal intubation without muscle relaxants using propofol and varying doses of fentanyl].

Tsuda A, Yasumoto S, Akazawa T, Nakahara T. Tsuda A, et al. Among authors: akazawa t. Masui. 2001 Oct;50(10):1129-32. Masui. 2001. PMID: 11712351 Clinical Trial. Japanese.

10

Development of a dendritic cell-targeting lipopeptide as an immunoadjuvant that inhibits tumor growth without inducing local inflammation.

Akazawa T, Ohashi T, Nakajima H, Nishizawa Y, Kodama K, Sugiura K, Inaba T, Inoue N. Akazawa T, et al. Int J Cancer. 2014 Dec 15;135(12):2847-56. doi: 10.1002/ijc.28939. Epub 2014 May 14. Int J Cancer. 2014. PMID: 24789268

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

534 results

Search Page

Filters